The penetration of ceftibuten into the respiratory tract

Chest

Volumn 116, Issue 2, 1999, Pages 369-374

  Krumpe, Peter ^a   Lin, Chin Chung ^b   Radwanski, Elaine ^b   Cayen, Mitchell N ^b   Affrime, Melton B ^b  

^a VA Sierra Nevada Health Care System   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Ceftibuten; Pharmacokinetics; Respiratory tract; Tissue penetration

Indexed keywords

CEFTIBUTEN;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BRONCHOSCOPY; CLINICAL ARTICLE; DOSE RESPONSE; DRUG HALF LIFE; DRUG PENETRATION; DRUG TISSUE LEVEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LUNG BIOPSY; LUNG LAVAGE; LUNG PARENCHYMA; MALE; MINIMUM INHIBITORY CONCENTRATION; NOSE SECRETION; PRIORITY JOURNAL; RESPIRATORY TRACT DISEASE;

EID: 0032775177     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.116.2.369     Document Type: Article

References (19)

1. Bauernfeind A. Ceftibuten and bactericidal kinetics. Comparative in vitro activity against enterobacteriaceae producing extended spectrum β-lactamases. Diagn Microbiol Infect Dis 1990; 14:89-92
2. Jones RN. Ceftibuten: a review of antimicrobial activity, spectrum and other microbiologic features. Pediatr Infect Dis J 1993; 12(suppl):S37-S44
3. Jones RN, Barry AL. Antimicrobial activity, spectrum and recommendations for disk diffusion susceptibility testing of ceftibuten (7432-S: SCH 39720), a new orally administered cephalosporin. Antimicrob Agents Chemother 1988; 32:1576-1582
4. Barr WH, Lin CC, Radwanski E, et al. The pharmacokinetics of ceftibuten. Diagn Microbiol Infect Dis 1991; 14:89-92
5. Lin C, Radwanski E, Affrime M, et al. Multiple-dose pharmacokinetics of ceftibuten in healthy volunteers. Antimicrob Agents Chemother 1995; 39:356-358
6. Chirurgi VA, Edelstein H, Oster SE, et al. Ceftibuten versus cefaclor for the treatment of bronchitis. J Antimicrob Chemother 1991; 28:577-580
7. Kammer RB, Ress R. Randomized comparative study of ceftibuten versus cefaclor in the treatment of acute lower respiratory tract infections. Diagn Microbiol Infect Dis 1991; 14:101-105
8. Hayashi I, Onuma K, Hasuike M, et al. Clinical examination of ceftibuten in acute bronchitis [in Japanese]. Jpn J Antibiot 1990; 43:761-767
9. McCabe R, Rumans L, Perrotta R, et al. Comparison of the efficacy and safety of ceftibuten and cefaclor in the treatment of pneumonia and bronchiectasis. J Chemother 1993; 5:124-132
10. Pan HT, Kumari P, Lim J, et al. Determination of a cephalosporin antibiotic, ceftibuten, in human plasma with column-switching high-performance liquid chromatography with ultraviolet detection. J Pharm Sci 1992; 81:663-666
11. Marlin GE, Nicholls AJ, Funnell GR, et al. Penetration of cefaclor into the bronchial mucosa. Thorax 1984; 39:813-817
12. Valcke Y, Pauwels R, Van Der Straeten M. Pharmacokinetics of antibiotics in the lung. Eur Respir J 1990; 3:715-722
13. Nix DE, Goodwin SD, Peloquin CA, et al. Antibiotic tissue penetration and its relevance: models of tissue penetration and their meaning. Antimicrob Agents Chemother 1991; 35:1947-1952
14. Carbon C. Significance of tissue levels for prediction of antibiotic efficacy and determination of dosage. Eur J Clin Microbiol Infect Dis 1990; 9:510-516
15. Lin C, Lim J, Radwanski E, et al. Pharmacokinetics and dose proportionality of ceftibuten in men. Antimicrob Agents Chemother 1995; 39:359-361
16. Andrews JM, Wise R, Baldwin DR, et al. Concentrations of ceftibuten in plasma and the respiratory tract following a single 400 mg dose. Int J Antimicrob Agents 1995; 5:141-144
17. Wise R. The pharmacokinetics of the oral cephalosporins: a review. J Antimicrob Chemother 1990; 26(suppl E):13-20
18. Baldwin DR, Andrews JM, Wise R, et al. Bronchoalveolar distribution of cefuroxime axetil and in vitro efficacy of observed concentrations against respiratory tract pathogens. J Antimicrob Chemother 1992; 30:377-385
19. Baldwin DR, Wise R, Andrews JM, et al. Concentrations of cefpodoxime in serum and bronchial mucosal biopsies. J Antimicrob Chemother 1992; 30:67-71